BRIT1 regulates p53 stability and functions as a tumor suppressor in breast cancer

Carcinogenesis

Volumn 34, Issue 10, 2013, Pages 2271-2280

  Zhang, Bo ^a   Wang, Edward ^b   Dai, Hui ^b   Hu, Ruozhen ^b   Liang, Yulong ^c   Li, Kaiyi ^c   Wang, Guobin ^a   Peng, Guang ^a,b   Lin, Shiaw Yih ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 C TERMINUS REPEAT INHIBITOR OF HUMAN TELOMERASE EXPRESSION 1 PROTEIN; PROTEIN MDM2; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CELL PROLIFERATION; CELL TRANSFORMATION; COLONY FORMATION; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; TRANSCRIPTION REGULATION; UBIQUITINATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; NERVE TISSUE PROTEINS; PROTEIN BINDING; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UBIQUITINATION;

EID: 84885128972     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt190     Document Type: Article

References (54)

1. Lin, S.Y. et al. (2003) Multiple tumor suppressor pathways negatively regulate telomerase. Cell, 113, 881-889.
2. Jackson, A.P. et al. (1998) Primary autosomal recessive microcephaly (MCPH1) maps to chromosome 8p22-pter. Am. J. Hum. Genet., 63, 541-546.
3. Rai, R. et al. (2006) BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell, 10, 145-157.
4. Jeffers, L.J. et al. (2008) Distinct BRCT domains in MCPH1/BRIT1 mediate ionizing radiation-induced focus formation and centrosomal localization. Oncogene, 27, 139-144.
5. Peng, G. et al. (2009) BRIT1/MCPH1 links chromatin remodelling to DNA damage response. Nat. Cell Biol., 11, 865-872.
6. Wood, J.L. et al. (2007) MCPH1 functions in an H2AX-dependent but MDC1-independent pathway in response to DNA damage. J. Biol. Chem., 282, 35416-35423.
7. Wu, X. et al. (2009) Microcephalin regulates BRCA2 and Rad51-associated DNA double-strand break repair. Cancer Res., 69, 5531-5536.
8. Liang, Y. et al. (2010) BRIT1/MCPH1 is essential for mitotic and meiotic recombination DNA repair and maintaining genomic stability in mice. PLoS Genet., 6, e1000826.
9. Bork, P. et al. (1997) A superfamily of conserved domains in DNA damage responsive cell cycle checkpoint proteins. FASEB J., 11, 68-76.
10. Richardson, J. et al. (2011) Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation. Breast Cancer Res. Treat., 127, 639-648.
11. Brüning-Richardson, A. et al. (2011) ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival. Br. J. Cancer, 104, 1602-1610.
12. Abraham, R.T. (2001) Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev., 15, 2177-2196.
13. Shiloh, Y. (2003) ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer, 3, 155-168.
14. Bakkenist, C.J. et al. (2004) Initiating cellular stress responses. Cell, 118, 9-17.
15. Zhou, B.B. et al. (2004) Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat. Rev. Cancer, 4, 216-225.
16. Hoeijmakers, J.H. (2001) Genome maintenance mechanisms for preventing cancer. Nature, 411, 366-374.
17. Lin, S.Y. et al. (2005) BRIT1/MCPH1 is a DNA damage responsive protein that regulates the Brca1-Chk1 pathway, implicating checkpoint dysfunction in microcephaly. Proc. Natl Acad. Sci. USA, 102, 15105-15109.
18. Xu, X. et al. (2004) Microcephalin is a DNA damage response protein involved in regulation of CHK1 and BRCA1. J. Biol. Chem., 279, 34091-34094.
19. Alderton, G.K. et al. (2006) Regulation of mitotic entry by microcephalin and its overlap with ATR signalling. Nat. Cell Biol., 8, 725-733.
20. Morrison, A.J. et al. (2004) INO80 and gamma-H2AX interaction links ATP-dependent chromatin remodeling to DNA damage repair. Cell, 119, 767-775.
21. van Attikum, H. et al. (2004) Recruitment of the INO80 complex by H2A phosphorylation links ATP-dependent chromatin remodeling with DNA double-strand break repair. Cell, 119, 777-788.
22. Pittman, D.L. et al. (1998) Meiotic prophase arrest with failure of chromosome synapsis in mice deficient for Dmc1, a germline-specific RecA homolog. Mol. Cell, 1, 697-705.
23. Yoshida, K. et al. (1998) The mouse RecA-like gene Dmc1 is required for homologous chromosome synapsis during meiosis. Mol. Cell, 1, 707-718.
24. Chan, K. et al. (2002) High-density allelotyping of chromosome 8p in hepatocellular carcinoma and clinicopathologic correlation. Cancer, 94, 3179-3185.
25. DeMarzo, A.M. et al. (2003) Pathological and molecular aspects of prostate cancer. Lancet, 361, 955-964.
26. Lassus, H. et al. (2001) Comparison of serous and mucinous ovarian carcinomas: distinct pattern of allelic loss at distal 8p and expression of transcription factor GATA-4. Lab. Invest., 81, 517-526.
27. Miller, B.J. et al. (2003) Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions. Am. J. Hum. Genet., 73, 748-767.
28. Pribill, I. et al. (2001) High frequency of allelic imbalance at regions of chromosome arm 8p in ovarian carcinoma. Cancer Genet. Cytogenet., 129, 23-29.
29. Shao, J.Y. et al. (2000) Genome-wide allelotype analysis of sporadic primary nasopharyngeal carcinoma from southern China. Int. J. Oncol., 17, 1267-1275.
30. Thor, A. et al. (2002) Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. Hum. Pathol., 33, 628-631.
31. Veltman, J. et al. (2003) Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res., 63, 2872-2880.
32. Chaplet, M. et al. (2006) BRIT1/MCPH1: a guardian of genome and an enemy of tumors. Cell Cycle, 22, 2579-2583.
33. Gordon, D.J. et al. (2012) Causes and consequences of aneuploidy in cancer. Nat. Rev. Genet., 13, 189-203.
34. Luijsterburg, M.S. et al. (2011) Chromatin and the DNA damage response: the cancer connection. Mol. Oncol., 5, 349-367.
35. Hanahan, D. et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-676.
36. Yang, S.Z. et al. (2008) MCPH1/BRIT1 cooperates with E2F1 in the activation of checkpoint, DNA repair and apoptosis. EMBO Rep., 9, 907-915.
37. Levine, A.J. et al. (2009) The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer, 9, 749-758.
38. Vousden, K.H. et al. (2009) Blinded by the light: the growing complexity of p53. Cell, 137, 413-431.
39. Laptenko, O. et al. (2006) Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ., 13, 951-961.
40. Raycroft, L. et al. (1990) Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science, 249, 1049-1051.
41. Kruse, J.P. et al. (2009) Modes of p53 regulation. Cell, 137, 609-622.
42. Vousden, K.H. et al. (2007) p53 in health and disease. Nat. Rev. Mol. Cell Biol., 8, 275-283.
43. Barak, Y. et al. (1993) MDM2 expression is induced by wild type p53 activity. EMBO J., 12, 461-468.
44. Manfredi, J.J. (2010) The MDM2-p53 relationship evolves: MDM2 swings both ways as an oncogene and a tumor suppressor. Genes Dev., 24, 1580-1589.
45. Wade, M. et al. (2010) The p53 orchestra: MDM2 and MDMX set the tone. Trends Cell Biol., 20, 299-309.
46. Lakin, N.D. et al. (1999) Regulation of p53 in response to DNA damage. Oncogene, 18, 7644-7655.
47. Harris, S.L. et al. (2005) The p53 pathway: positive and negative feedback loops. Oncogene, 24, 2899-2908.
48. Pluquet, O. et al. (2001) Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett., 174, 1-15.
49. Lavin, M.F. et al. (2006) The complexity of p53 stabilization and activation. Cell Death Differ., 13, 941-950.
50. Huart, A.-S. et al. (2009) CK1a plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability. J. Biol. Chem., 284, 32384-32394.
51. Barkova, J. et al. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature, 434, 864-870.
52. Di Micco, R. et al. (2006) Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature, 444, 638-642.
53. Vogelstein, B. et al. (2004) Cancer genes and the pathways they control. Nat. Med., 10, 789-799.
54. Brosh, R. et al. (2009) When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer, 9, 701-713.